Clinical Trials Logo

Metastatic Breast Cancer clinical trials

View clinical trials related to Metastatic Breast Cancer.

Filter by:

NCT ID: NCT04872608 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer

Start date: May 2021
Phase: Phase 1
Study type: Interventional

The researchers are doing this study to find out whether the study drug onapristone ER, combined with the standard treatment for your cancer (letrozole and palbociclib), is a safe treatment for people who have metastatic or unresectable ER+/PR+/HER2- breast cancer. The researchers will test different doses of the study drug to find the highest dose that causes few or mild side effects.

NCT ID: NCT04869943 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

ARTEST
Start date: June 30, 2021
Phase: Phase 3
Study type: Interventional

To demonstrate the efficacy of enobosarmin the treatment of androgen receptor positive (AR+) and estrogen receptor positive (ER+) metastatic breast cancer (MBC) as measured by radiographic progression free survival (rPFS).

NCT ID: NCT04857619 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer

Start date: April 30, 2021
Phase:
Study type: Observational

This multicountry, multicenter, retrospective, non-interventional study involving patients diagnosed with HER2-positive unresectable or metastatic breast cancer mBC will be conducted to understand the demographic and clinico-pathological profile of the patients, diagnostic practices for human epidermal growth factor receptor 2 (HER2) status, current treatment landscape and sequencing of therapies, associated burden of toxicities with all lines of treatment (LOTs), and survival outcomes in the real-world setting.

NCT ID: NCT04834778 Recruiting - Gastric Cancer Clinical Trials

A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)

Start date: April 12, 2021
Phase: Phase 1
Study type: Interventional

Study HC-404-FCP-2011 is a first in human, Phase 1a, multi-center, open-label study to establish the maximum tolerated dose (MTD) and evaluate the safety and tolerability of oral dosing of HC-5404-FU in a dose-escalating fashion. Up to 24 qualified subjects at 3 to 5 US sites, who have specific tumor types of renal cell carcinoma (RCC), gastric cancer (GC), metastatic breast cancer (MBC) or small cell lung cancer (SCLC) will receive HC-5404-FU. Every effort will be made to ensure approximately 50% of all subjects enrolled will be subjects with RCC. The starting dose level is 25 mg twice daily (BID), escalating to 50, 100, and 200 mg BID as safety allows, following the Bayesian Optimal Interval (BOIN) design. If MTD is not reached even at the maximum dose level (200 mg BID is well tolerated), a higher dose level may be evaluated based on the safety monitoring committee (SMC) recommendations after a comprehensive review of the PK, safety, and efficacy data generated from the study. This Phase 1a will be expanded into a Phase 1b/2a study through a protocol amendment and will then assess the dose and tumor type(s) selected in Phase 1a as the most appropriate for further clinical development. Subjects will be dosed until unacceptable toxicity, disease progression per immune-related Response Evaluation Criteria in Solid Tumors (iRECIST), subject withdrawal, any other administrative reasons, or after 2 years of treatment, whichever occurs first. Efficacy will be assessed via Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1); computed tomography (CT) scans will be conducted every 6 weeks. Safety, including occurrence of dose-limiting toxicities (DLTs), pharmacokinetics (PK), and biomarker parameters will also be assessed.

NCT ID: NCT04796324 Recruiting - Clinical trials for Metastatic Breast Cancer

Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Start date: March 1, 2021
Phase: Phase 2
Study type: Interventional

The purpose is to investigate anti-tumor effect of ixabepilone in patients with locally recurrent or metastatic breast cancer (mBC) selected by the Ixabepilone DRP after failure of an anthracycline and taxanes.

NCT ID: NCT04770129 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

Real-World Data on Clinical Characteristics, Demographics, and Outcomes of Patients With Metastatic Breast Cancer in Turkey

Start date: February 2021
Phase:
Study type: Observational

This study is planned as a secondary data use (SDU) study and the data collection will be performed retrospectively. Patients who presented to the participating sites with metastatic breast cancer will be defined, and patients' data will be recorded into a database.

NCT ID: NCT04740918 Recruiting - Clinical trials for Metastatic Breast Cancer

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

KATE3
Start date: May 4, 2021
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy, safety and patient-reported outcomes of trastuzumab emtansine plus atezolizumab compared with trastuzumab emtansine plus placebo in participants with HER2-positive and PD-L1-positive LABC or MBC.Participants must have progressed either during or after prior trastuzumab- (+/- pertuzumab) and taxane-based therapy for LABC/MBC; or during (or within 6 months after completing) trastuzumab- (+/-pertuzumab) and taxane-based therapy in the neoadjuvant and/or adjuvant setting.

NCT ID: NCT04734262 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib and Tislelizumab in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer

Start date: January 30, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of tislelizumab in combination with sitavatinib in advanced triple-negative breast cancer patients.

NCT ID: NCT04733417 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.

Start date: March 10, 2021
Phase: Phase 2
Study type: Interventional

The study is being conducted to assess the efficacy and safety of SHR6390 combined with famitinib in the treatment of advanced or metastatic breast cancer that progress in 1-2 line endocrine therapy.

NCT ID: NCT04720664 Not yet recruiting - Breast Cancer Clinical Trials

Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer

OASIS
Start date: May 2021
Phase: Phase 2
Study type: Interventional

This is a phase II single arm, open-label study of SM-88 used with methoxsalen, phenytoin, and sirolimus (MPS) in metastatic HR+/HER2- breast cancer. It is designed to determine efficacy, defined as the objective response rate (ORR) of this investigational treatment. It is hypothesized that SM-88 used with MPS will lead to significant anti-tumor responses with acceptable toxicities in patients with metastatic HR+/HER2- breast cancer.